Skip to main content
Premium Trial:

Request an Annual Quote

Amersham Renames Units, Changes Logo, Consolidates Ticker Symbols

NEW YORK, Oct. 16 - Amersham has changed the names of its two businesses to Amersham Biosciences and Amersham Health, the company said.

Amersham Biosciences, Amersham’s life-sciences business, was formerly known as Amersham Pharmacia Biotech. Amersham Health, the group’s medical diagnostics and therapy business, was formerly called Nycomed Amersham Imaging.

The firm, based in London, also said all of its units will adopt a new logo and that it will begin trading under a new ticker symbol—AHM—on the stock exchanges in London, New York, and Oslo. The company’s shares previously were listed as NAM in London, NYE in New York, and NYA in Oslo.

“Having a consistent identity will give us greater visibility in the marketplace and simplify the perception of our company for all our stakeholders,” Sir William Castell, Amersham’s CEO, said in a statement released on Monday.

Castell is scheduled to ring the closing bell at the New York Stock Exchange on Oct. 17 to mark his company’s new corporate identity and ticker symbol, according to the statement.  

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.